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Summary 
Cells of monocytic lineage can initiate extravascular fibrin deposition via expression of blood 
coagulation mediators. This report is about experiments on three mechanisms with the potential 
to modulate monocyte-initiated coagulation. Monocyte procoagulant activity was examined as 
a function of lipid cofactor, protein cofactor, and specific inhibitor expression during short-term 
culture in vitro.  Lipid cofactor activity was measured as the initial rate of factor X  activation 
by intrinsic-pathway components, the assembly of which depends on this cofactor. Lipid cofactor 
activity levels changed by <30% during 48-h culture. Protein cofactor, i.e., tissue factor (TF) 
antigen was measured by enzyme immunoassay.  It increased from 461 pg/ml to a maximum 
value of 3,550 pg/ml at 24 h and remained at 70% of this value. Spedfic TF activity, measured 
as factor VII-dependent factor X activation rate, decreased from 54 to 18 nM FXa/min between 
24 and 48 h. TF activity did not correlate well with either lipid cofactor or TF protein levels. 
In contrast, the decrease in TF activity coincided in time with maximal expression of tissue 
factor  pathway inhibitor (TFPI)  mRNA, which was  determined using reverse transcriptase 
polymerase  chain reaction (RT-PCR),  and with maximal TFPI protein levels measured  by 
immunoassay. The number of mRNA copies coding for TFPI and TF in fleshly isolated blood 
monocytes were 46 and 20 copies/cell, respectively. These values increased to 220 and 63 copies/cell 
during short-term cell culture in the presence of endotoxin. Results demonstrate concomitant 
expression by monocytes of genes coding for both the essential protein cofactor and the specific 
inhibitor of the extrinsic coagulation pathway. Together with functional and antigenic analyses, 
they also imply that the initiation of blood dotting by extravascular monocyte/macrophages 
can be modulated locally by TFPI independently of plasma sources of the inhibitor. 
H 
'emostatic balance is maintained by localized crosscata- 
￿9  lytic and inhibitory reactions connecting the intrinsic, 
extrinsic,  and common coagulation pathways (1-4).  These 
reactions  are ultimately dependent on tissue factor  (TF) 1, 
an integral membrane protein selectively expressed by proco- 
agulant cells. TF procoagulant activity is associated with 
monocytes/macrophages  and perturbed endothelial cells, but 
not with polymorphonuclear leukocytes, lymphocytes,  or 
platelets (4-6). TF functions as an essential cofactor for factor 
t Abbreviations used in this pa~r: EIA, enzyme immunoassay; LPSR, low 
protein serum replacement; Mo-MLV-RT,  Moloney murine leukemia  virus 
R~ KT, reverse  transcriptase;  TF, tissue factor; TFPI, tissue factor pathway 
inhibitor. 
Parts of this study have been published in abstract form (1993. FASEB 
[Fed. Am. Soc. Ex  F Biol.]J. 7:Al16). 
VIIa in the extrinsic pathway-protease  complex and is there- 
fore indispensable for rapid proteolytic activation of coagula- 
tion factors IX and X. In addition, TF facilitates the activa- 
tion of factor VII by factor Xa and is required for efficient 
inhibition of TF/VIIa complexes by antithrombin III (2, 7, 
8). Thus, identification  of mechanisms that regulate TF ex- 
pression and function on procoagulant membranes is a neces- 
sary step in understanding how hemostatic balance is main- 
tained in vivo. 
Available information suggests that among the TF-pathway 
inhibitors  described  to  date,  antithrombin  III  (7)  and 
lipoprotein-associated coagulation inhibitor (9-11) are likely 
the most important regulators in vivo. This latter inhibitor 
is also referred to as extrinsic pathway inhibitor (EPI) and 
more recently as tissue factor pathway inhibitor (TFPI) (12-15). 
TFPI is primarily associated with lipoproteins,  and is found 
in human plasma at a concentration of m3 nM. In sharp con- 
trast with antithrombin III, TFPI does not inhibit thrombin 
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trinsic pathway (9,  10). Structurally,  TFPI is related to the 
inhibitor family of the pancreatic trypsin inhibitor (kunitz- 
type) of protein inhibitors of proteinases (9, 10). It has been 
recently shown that TFPI binds TF, factor VII,  and factor 
Xa on cell membranes in vitro (16).  Functionally, TFPI in- 
hibits the activation of factors IX and X by TF--factor VIIa 
complexes and the amidolytic activity of factor VIIa and Xa 
toward small synthetic substrates.  Plasma concentration  of 
TFPI is at least 10-fold lower than its dissociation constant 
with factor Xa (10), and of the same order as its dissociation 
constant with TF/factor VII on cell membranes (16). These 
observations suggest that TFPI must be generated close to 
its proposed site of action on procoagulant surfaces (9, 10). 
However, de novo expression of TFPI by nontransformed 
procoagulant calls other than endothelial cells remains to be 
demonstrated unambiguously. 
Monocytes and macrophages are characteristically present 
in neoplastic, inflammatory, and atherosderotic lesions. Ex- 
pression of TF activity by infiltrating monocyte/macrophages 
is believed to be an important factor in the thromboembolic 
manifestation  often associated with these pathological processes 
(17-24). Monocytes also express the lipid cofactor necessary 
for efficient assembly of intrinsic and common pathway coagu- 
lation proteases. The physicochemical characteristics of mem- 
brane lipids have been shown to influence the functional ac- 
tivity of TF (25).  The present  studies examine kinetics of 
monocyte procoagulant expression during short-term culture 
in vitro in the presence of endotoxin. Three hypothetical mech- 
anisms of TF control amenable to experimental testing are 
investigated: namely, modulation of TF activity by changes 
in lipid membrane cofactor, regulation of activity via changes 
in levels of TF protein, and regulation via de novo synthesis 
of specific  TF inhibitor. 
Materials  and Methods 
Monocyte Isolation and Culture.  Human mononuclear cells were 
obtained by fractionation  of 200-500  ml heparinized or citrated 
blood by differential sedimentation and centrifugation  in density 
gradients (26, 27). Mononuclear  cell populations  were enriched 
in monocytes by centrifugation  through hypertonic  Pereoil gra- 
dients, 45% Percoil in NaC1 at 9.3 mg/ml. Contaminating phtelets 
were removed by repeated washes with sterile physiologic saline 
solution. Ceils in the purified population were 85-95% monocytes 
and 5-15% lymphocytes by morphologic  criteria (Wright's  stain 
and nonspecific esterase stains) (4). Cells were >95% viable as de- 
termined by trypan blue dye e~lusion and contained <1 phtelet/10 
nucleated cells. For culture, these monocyte-enriched populations 
were resuspended at 4-5  x  106/ml in serum-free medium M199 
supplemented with 2% low protein  serum replacement (LPSR; 
Sigma Chemical Co., St. Louis, MO), containing 100 U/m1 peni- 
cillin, 100/~g/rnl streptomycin, and 2 #g/ml of  bacterial LPS. (Fach- 
erichia coli Serotype 0127:B8; Sigma Chemical Co.). In selected ex- 
periments, cells were also incubated in the absence of LPS-LPSR 
stimulus. Cultures  were maintained up to 48 h in polypropylene 
culture tubes in a slanted position at 37~  and in an atmosphere 
of 95% air, 5% CO2. Cell viability decreased by <7% during the 
observation interval and the range of total cell counts remained 
within 4.47  _+  1.4%, of initial counts in replicated cultures. 
Identification of mRNAs Coding for TFP1 and TE  Steady-state 
levels of TF and TFPI mRNA were measured by PCR amplification 
ofcDNAs transcribed from RNA using reverse transcriptase (RT) 
and oligo dT primers. Amplified DNA was measured fluorometri- 
cally  and  the  PCR  efficiency was  determined  by analysis of 
amplification kinetics on each primer-template  set. The rationale 
for this approach is based on the fact that the final amount of DNA 
generated by PCR after each cycle is determined not only by the 
number of copies initially present but also by the overall experimental 
efficiency. These two factors can be related by the formula: N  = 
No (1  +  E)  n where N is the final amount of DNA generated, No 
is the amount initially present and E is the overall amplification 
efficiency. The term E includes the combined effect of hybridiza- 
tion efficiency, enzyme decay, and other factors on the deviation 
of reaction kinetics from the optimal theoretical, N  =  No2  n. The 
observed efficiency, Eob,, was derived from the slope of linear plots 
of log DNA concentration  vs. cycle number.  Eob, was corrected 
for decay of Taq DNA polymerase activity during reaction time 
in order to estimate the initial efficiency, E~. Decay constant of Taq 
polymerase was calculated assuming a half-life of 40 win at 95~ 
The overall efficiency  E was approximated as the arithmetic average 
of initial and observed efficiendes such that E  ~  (Ei  +  Eoh)/2. 
Total RNA was isolated from monocytes by a variation of the 
guanidinium thiocyanate method (28) using RNAzol reagent from 
Cinna Scientific, Inc. (Friendswood, TX). The RNA was washed 
with  ethanol,  resuspended  in  H20,  and  quantified  spec- 
trophotometrically  by measuring absorbance at 260 nm. Prepara- 
tions of RNA used in these studies had 260/280 optical density 
ratios of 1.8 and 0.6  _+ 0.5/~g of total RNA was recovered from 
106 ceils. Purified RNA samples were stored in ethanol at  -20~ 
The mRNA in 0.5 Izg total RNA was transcribed to cDNA in 
reaction mixtures con~inlng 2.1 U/ml of Moloney routine leukemia 
virus reverse transcriptase (Mo-MLV-RT), 2.1 ~  oligo dT primers, 
4 mM MgCz, 0.8 ~M each of demg,  nucleoside triphosphates, and 
0.8 U/#I of RNase inhibitor, in 10 mM Tris-HCl buffer, pH 8.3, 
with 40 mM KCI. Reactions were carried at 42~  for 1 h at which 
time Mo-MLV-RT was inactivated by heating at 99~  for 5 win. 
A known number of copies of control RNA template transcribed 
from plasmid pAW109 containing Iblcx sequences was incubated 
under conditions identical to those used for monocyte RNA. This 
control was used to confirm the linearity of the RT reaction and 
to validate the method for determination  of efficiency by PCR 
amplification kinetics. In some experiments reactions included an 
excess of mRNA (0.25 ~g of rabbit B-globin mRNA; Clontech, 
Palo Alto, CA) to insure that reaction conditions allowed for tran- 
scription of all mRNA in RT mixture.  Mixtures with either no 
RT or RNA were also cycled to control for the possibility of am- 
plifying traces of genomic DNA that may be present in the total 
RNA preparations and to detect possible contamination of reagents, 
respectively. 
Samples, 10 #1 each, from each RT mixture were adjusted to 
3 mM of MgCI2 and amplified for 35 cycles with Taq-polymerase, 
2.5 ~/ml,  using 0.15/zM each of oligonucleotide  primers. Each 
set of primers frame a 528 and 513 base pair sequence starting at 
nucleotides 217 and 292 from the 5' end of the published cDNA 
translated  sequences of  TF  and  TFPI  respectively  (29,  30). 
Amplifications were carried in a thermocycler, 2 win at 95~  for 
one cycle, and 1 win at 95~  and 1 rain at 60~  for 35 cycles. 
All reagents used for RT-PCR were obtained from Perkin-Elmer 
Cetus (Norwalk,  CT). 
To measure amplification kinetics, reaction mixtures were rap- 
idly sampled during the melting step of cycles 20-35, and the con- 
centration  of DNA in each sample was determined fluorometri- 
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with calf thymus DNA and the sensitivity of the assay was ad- 
justed to give a linear signal with concentrations ranging from 2 
to 100/zg DNA/ml. The purity of the PCR products was ana- 
lyzed  in representative  experiments  by agarose  gel (1.2% low melting 
point; Clontech) electrophoresis using ethidium bromide to idea- 
tify the size of DNA bands. The specificity of the amplification 
reaction was further demonstrated by subcloning and sequencing 
of  randomly chosen amplified  transcripts using PCR II vector (In- 
vitrogen, San Diego, CA) and Sequenase 2, sequencing  kit (United 
States Biochemical Corp., Cleveland, OH). 
Detection of TF and TFPI Protein by Iramunoassay.  TF antigen 
on monocytes was measured in cell lysates by enzyme immuno- 
assay (EIA) using Immunobind Tissue Factor kit from American 
Diagnostica, Inc. (Greenwich, CT). In this assay the "IF antigen 
in cell extracts and supernatants is captured specifically  with mono- 
clonal antibody that recognizes  intact TF (32). Standard  curves  were 
constructed using a recombinant 47-kD TF protein. TFPI antigen 
was measured using EIA Immunobind TFPI Kit from American 
Diagnostica with minor modifications.  The instructions in the kit 
prospectus were followed except that reagent volumes were 50/~1 
instead of the 100/zl recommended and the chromogenic reaction 
was extended to 90 min instead of 30 rain. Standard curves were 
constructed using a recombinant 43-kD TFPI protein. 
Measurement of  Procoagulant Activity.  Procoagulant  activity was 
quantified using a one-stage clotting assay with pooled human 
plasma (George King, Bio-Medical, Inc., Overland Park, KS) as 
described previously (33). 60 #1 of the sample were mixed to 60 
/zl of 0.025 M CaCIz and 60 #1 of citrated plasma. Clotting times 
were measured  using a fibrometer  (Becton  Dickinson & Co., Moun- 
tain View, CA) and converted to arbitrary TF units using loga- 
rithmic plots of clotting times vs. dilution of a standard TF solu- 
tion prepared with crude human brain homogenate. By definition, 
1,000 mU/ral of procoagulant is the concentration of TF giving 
a coagulation time of 50 s in this test. 
Measurements of Factor X  Activation Rates on Monocytes.  Acti- 
vation of factor X via the extrinsic and intrinsic pathway protease 
complex assembled  on monocytes was measured as described pre- 
viously (4, 6). Briefly,  reaction mixtures contained 2.6  x  10~/ml 
monocytes, 5 mM CaCh, 5 nM factor VIIa in 50 mM Tris buffer, 
0.15 M  NaC1, and 0.5 mg/ml ovalbumin, pH  7.2-7.4.  Reac- 
tions were initiated with factor X at 70 nM. 40/tl samples were 
withdrawn at 30 s intervals and mixed with 40/zl of 0.2 M EDTA 
in 50 mM  Tris, 0.8  N  NaCI,  pH  8.3,  in  microplate  wells. 
Chromogenic  substrate either  S-2222 (N-Benzoyl-t-isoleucyl-L- 
glutamyl-glycyl-L-arginine~p-nitroanilide  hydrochloride)  or S-2765 
(N-cx-Benzyloxycarbonyl-n-arginy-L-glycyl-t-arginine-p-nitroani- 
lide-dibydrochloride),  both from Kabi  Vitrum (Stockholm,  Sweden) 
was added (0.32 and 0.12 mg/ml, respectively)  and initial rates of 
p-nitrophenyl generation were measured using a Vmax,microplate 
reader (Molecular Devices Corp., Menlo Park, CA)..Activation of 
factor X via intrinsic pathway was measured in reaction mixtures 
constructed as above except that factor VIIa was replaced by 0.8 
nM factor IXa 0.8 nM and 1 nM factor VIII. Factor VIII was acti- 
vated to factor VIIIa with 0.5 nM thrombin added 30 s before ini- 
tiation of factor X activation reaction (4). 
Coagulation Factors.  Purified  human coagulation factors  X, IXa, 
and IX with specific activities of 125, 200, and 125-200 U/rag 
of protein,  respectively, were obtained from Enzyme Research 
Laboratories, Inc. (South Bend, IN).  Human factor Xa was pre- 
pared by activation of factor X with Russell Viper Venom as previ- 
ously described (4). Recombinant factor VIIa was kindly donated 
by Dr. Ulla Hedner (Novo Nordisk A/S, Copenhagen, Denmark). 
This recombinant product is homogeneous as determined by high- 
performance liquid chromatography  in the supplier's laboratory and 
has activity of -~2180 U/m1 as determined by dotting test with 
monodeficient human plasma. The factors IX, X, and IXa used 
are  dectrophoretically  homogenous  as  determined by sodium 
dodecyl  sulfate-polyacrylamide  electrophoresis and functionally  pure 
in coagulation tests with monodeficient  human plasma as substrate. 
Immunopurified human factor VIII with specific activity greater 
than 3,000 U/mg of  protein was obtained  from Armour Pharmaceu- 
tical Co. (Kankakee, IL). 
Results 
Monocyte Procoagulant Activity during Short-term Culture In 
Vitro  Mononuclear phagocytes isolated from human blood 
were incubated at 4-5  x  106/ml for 0, 3, 20 and 48 h. Cells 
were suspended in medium M-199 with 2%  LPSR and 2 
/zg/ml of bacterial LPS. Incubation under these conditions 
resulted in  morphologic and functional changes  that  are 
comparable to those observed in monocyte/macrophages at 
extravascular, inflammatory, and atheriosderotic sites (18, 21, 
22, 33).  These changes indude increases in size and proco- 
agulant activity and decreases in nucleus to cytophsmic ratios. 
Total levels of procoagulant activity in the monocyte suspen- 
sion, measured as the shortening of plasma clotting times, 
were maximal between 18-24 h and decreased to 75% of  max- 
imum by 48 h  (Fig.  1).  The rate of procoagulant activity 
accumulation was estimated to be maximal between 6 and 
15 h of culture at a value of 39.8 mU/ml/h. After 15 h the 
average rate of procoagulant output decreased rapidly and was 
only 1.0 mU/ml/h from 15 to 22 h. The rapid changes in 
procoagulant activity generation in the absence of cell death 
suggest specific modulation of this activity during matura- 
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Figure 1.  Procoagulant  activity  and TF antigen expressed by mono- 
cytes during  culture. Procoagulant  activity  (closed  circles) was measured  as 
the shortening  of  plasma  dotting time  upon mixing  with the cell  suspen- 
sion. Activity  is expressed in milliunits  (mU) and was quantified  using 
a reference  curve  constructed  with human  brain homogenate  as a TF stan- 
dard. In this assay, 1 U is the concentration  of  TF that shortened  the dot- 
ting time of recalcitied  plasma to 50 s. TF antigen  (open circles) was mea- 
sured by enzyme  immtmoassay  using  a monodonal  antibody  that recognizes 
intact TF. TF antigen  was quantified  using a reference  curve  constructed 
with human  recombinant  TF as a standard.  Data are from  one of six similar 
experiments. Mean and SE of normalized  values  from additional  e~peri- 
ments are in Table 1. 
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Figure 2.  Specific TF activity and lipid cofactor activity expressed  by 
monocytes during culture. TF activity (closed  circles)  was measured in the 
presence of purified factors VIIa (5 nM) and X  (120 nM) as the initial 
rate of factor Xa generation in Tris buffer, 0.15 M NaC1, 4 mM CaC12, 
pH 7.3. Concentration of factor VIIa used was saturating and initial rates 
reflect concentration of functional TF expressed by cells. Lipid cofactor 
activity (open circles)  was measured independently of TF by substituting 
factor VIIa with intrinsic ptotease components, factor IXa (0.8 nM) and 
VIIIa (1 nM). These concentrations yield half maximal rates of Xa genera- 
tion. Rates reflect number of functional assembly sites expressed on the 
monocyte membrane. Data were obtained from one experiment with cells 
from the same donor used to obtain data in Fig. 1. Means and SE from 
additional experiments are in Table 1. 
tion. To determine if the decrease in procoagulant activity 
is associated with specific changes in TF activity, initial rates 
of factor Xa generation were measured in reaction mixtures 
assembled with purified human coagulation factors VIIa and 
X. Concentration of factor VIIa in these experiments was 
5 riM, i.e., similar to plasma concentration and saturating 
for membrane TF. This insures that observed rates reflect TF 
concentration rather than possible changes in the dissocia- 
tion/association rates of TF/VIIa interaction. Initial rates of 
factor X activation increased with time of culture and were 
maximal between 15 and 24 h but decreased to =30%  of 
maximum by 48 h  (Fig.  2 and Table 1). 
Monocyte Lipid  Cofactor Function during Short-term Cul- 
rum  The observed changes in TF activity could be, in theory, 
secondary to changes in the membrane lipid cofactor activity 
necessary for functional assembly of coagulation protease com- 
plexes (1, 2, 25). Lipid cofactor activity was measured as the 
ability of monocytes to provide membrane sites for eflicient 
assembly of the intrinsic factor X activating protease.  This 
protease complex, like the extrimic pathway protease TF/VIIa, 
is composed of a protein cofacmr, factor VIIIa, and an en- 
zyme component, factor IXa. However in contrast with TF, 
factor Villa is not an integral membrane protein but binds 
reversible to lipid surfaces with an apparent Ka of =10 -9 M 
(6, 34).  This characteristic  was exploited to measure lipid 
cofactor activity independently of changes in the protein 
cofactor, i.e., TF. The intrinsic pathway protease was assem- 
bled on monocytes cultured for 0--48 h using fixed and lim- 
iting concentrations of factor IXa and VIIIa (Fig. 2, dotted 
line, and Table 1). Rates of factor X activation by this pro- 
tease complex did not decrease significantly during mono- 
cyte maturation; instead, a modest increase in activity was 
observed during culture. This result indicates  that the de- 
crease in specific (i.e., factor VII dependent) TF activity ob- 
served (Fig. 2, solid line, and Table 1) is not likely due to con- 
comitant changes in protease assembly sites expressed during 
monocyte maturation in culture. 
TF Antigen Levels in Monocytes during Short-Term Culture. 
Levels of TF protein antigen in monocytes were measured 
by enzyme immunoassay at 0, 3, 24 and 48 h, after initiation 
of culture in the presence of stimulus. Results of these mea- 
surements (Fig.  1, and Table 1) show that TF antigen was 
present in freshly isolated monocytes at 178 pg/mg of total 
cell protein, increased to a maximum value of 1407 pg/mg 
(7.9-fold) by 24 h, and stayed at >70% of maximal values 
for up to 48 h. In contrast, specific TF activity measured 
Table  1.  TF Activity,  Lipid Cofactor Activity,  and TF Antigen Expressed during Monocyte Culture 
Culture time  TF activity*  Lipid cofactor activity  TF antigen*  TFPI Antigen 
h 
0  1.5  +  0.7  74  _+  6  13  +  2  45  _+  9 
3  8.5  _+  3.2  80  -+  4  22  +  7  51  _+  6 
24  100  _+  0.0  95  +  3  100  +  20  72  _+  8 
48  34.3  _+  4.5  96  _+  3  73  _+  20  98  +_  2 
(n  =  6)S  (n  =  6)  (n  =  5)  (n  =  5) 
* TF and lipid cofactor activity were measured as initial rate of factor X  activation in reaction mixtures with 2.0  x  10  ~ cell/ml, and either factor 
VIIa (5 nM) or factors IXa/VIIIa (0.8 and 1 nM). Rate values are normalized as percent of maximal rate measured during culture.  Maximal rates 
were 9.0  +  1.0 and 18  •  0.2 nM factor Xa/min for TF and lipid cofactor activity,  respectively. Lipid cofactor activity,  TF antigen, and TFPl 
antigen levds were  maximal at 24-48 h of culture. TF activity was maximal at 24 h of culture. 
* TF and TFPI antigens,  were quantified by EIA. Maximal value for tissue factor was  1.4 ng/mg of cell protein. Maximal value for tissue factor 
pathway inhibitor was 0.57 ng/mg of cell protein. 
S Data are mean  •  SE from n different monocyte cultures,  each with cells from a different donor. 
1850  Expression of Extrinsic Coagulation Pathway Inhibitor by Human Monocytes Figure 3.  Signal to product relation- 
ship for TFPI and TF mKNA in RT- 
PCK assay. Total KNA (0, 0.05, 0.2, 
0.4, 0.8, and 1/~g) isohted from mono- 
cytes after 3 h  in culture was reverse 
transcribed and amplified as indicated 
in Table 2. (~p) Results obtained using 
ethidium bromide and agarose gel dec- 
trophoresis;  (Bottom) results  from 
Hoechst dye 33258 and fluorometry for 
DNA quantitation. Note the increased 
sensitivity  and precision obtained with 
Hoechst dye method. Within the range 
ofmRNA levels measured, input RNA 
signal was directly related to amplified 
cDNA. 
kinetically was maximal at 24 h with a rate of 9.1  _+  1 nM 
factor Xa/min (Fig. 2, and Table 1) and decreased to 30% 
of this maximum by 48 h. In the absence of stimulus,  TF 
protein levels were five-, three-, and fourfold above those in 
freshly isolated monocytes at 3, 20, and 48 h of culture. TF 
activity measured kinetically in these cultures was maximal 
at 48 h, however, rate was only 1.5 nM factor Xa/min. The 
observed discrepancy between TF activity, lipid cofactor, and 
TF protein antigen levels suggest modulating of activity by 
specific TF pathway inhibitor. 
Expression of TFPl and TF mRNA by Monoo/tes  during  Short- 
Terra Culture.  The possibility  that human monocytes can 
regulate procoagulant activity via synthesis and expression 
of specific TF pathway inhibitor was explored by analysis of 
mKNA. Relative levels of mKNA coding for TFPI and TF 
expressed during monocyte culture were determined in total 
KNA preparations  isolated from monocytes after 0, 3, 24, 
and 48 h of culture.  KT and oligo dT primers  were used 
to generate eDNA from poly A mKNA in total KNA prepa- 
rations.  Two identical aliquots  of the KT reaction mixture 
were used as the template source to amplify specific eDNA 
sequences with synthetic oligonudeotide primers complemen- 
tary to either TFPI or TF  sequences. The PCK products 
yielded sharp  single bands of the expected size when ana- 
lyzed by gel electrophoresis and ethidium bromide staining 
(Figs. 3 and 4). The DNA sequences of amplified products 
were shown to have ~>99% homology with human TF and 
TFPI sequences stored in GenBank. Amounts of PCK product 
generated were proportional to initial amounts of total RNA 
included in the RT mixture (Fig. 3,  bottom). The nuraber 
of mRNA copies/cell for each gene was estimated from the 
average amplification  efficiency determined independently 
for each  primer  template  set  by  kinetic measurement of 
Figure  4.  Time course of amplified TF and TFPI eDNA. Detection 
using ethidium bromide and agarose gel electrophoresis.  Total KNA, 0.5 
/Lg isolated from monocytes was reverse transcribed and amplified as indi- 
cated in Table 2. Amplified products and standard DNA fragments (Hae 
III digest of phage RF Ox174)  were dectrophoresed in 1.2% agarose gel 
and stained with ethidium bromide. Amplified  TFPI cDNA and amplified 
TF eDNA are to the left and to the right of the standards,  respectively. 
For each cDNA, bands 1, 2, 3, and 4 were from mKNA samples isolated 
at 0, 3, 24, and 48 h of cnlture. The band from 0 time samples was not 
visible for TF eDNA and only faintly visible for TFPI eDNA. 
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TF  TFPI 
Monocyte* 
Maturation time  DNA*/zg  mRNAS copies/ceil  DNA/,g  mRNA copies/cell 
h 
0  0.27  +  0.07  (7)  22.0  0.35  _+  0.11  (7)  46.2 
3  0.63  +  0.16 (7)  50.9  0.65  _+ 0.16 (7)  83.6 
24  0.52  +  0.16 (7)  42.5  1.03  +  0.21 (7)  133.3 
48  0.53  +  0.04 (4)  42.6  1.70  _+  0.64 (3)  220.0 
* Total RNA 0.5/~g isolated from monocytes after the indicated culture intervals was used to generate eDNA from mRNA using 1 U//zl Mo-MLV- 
RT. Identical aliquots of the KT reaction mixture were amplified by PCR using sense and antisense primers, 0.15/~M each complementary to either 
TF or TFPI cDNA sequences. Taq polymerase was added at 2.5 U/100 ~1; deoxynucleoside triphosphates  at 1 mM each and MgCI2 at 2 mM. 
The reaction was carried in 10 mM Tris HCI buffer,  pH 8.3,  for 35 cycles, each cycle at 95~  for  1 min and at 60~  for  1 rain. 
t The amplified DNA was measured fluorometrically using Hoechst dye 33258 and calf thymus DNA as a standard.  No DNA was detected in cy- 
ded reaction mixtures that did not include either  RT or RNA. 
S The number of copies/monocyte  was estimated from the amounts, N, of DNA generated by PCR using the formula, N  =  No(1  +  E)~, where 
No is the initial number of copies of cDNA, E is the average efficiency and n is the number of cycles. The average efficiency was calculated from 
the observed e~iciency Fob, and the initial efficiency, Ei i.e., E  ~  *A(EI +  Eob,). The initial efficiency was calculated from Eo~ using the relationship 
Eob, =  F~e  -xt, where t is the time in minutes and 2~ is the decay constant for Taq polymerase with half-life of 40 rain at 95~  The observed efficien- 
cy Eob, was determined from the slope of semilogarithmic plots of N vs. cycle number. The E was 0.351  +  0.016 and 0.368  +_ 0.027 for TFPI and 
TF, respectively. To demostrate the reliability of E estimates, the E of control pAW109 RNA was determined directly, using known number of initial 
mRNA copies ranging from 0.15 to 1.25  x  104 and resulting in amplified DNA ranging from 0.13 to 5.4  x  1012 copies. The average efficiency 
was 0.75  +  0.06, which is within experimental error of the value 0.715 calculated from the kinetic measurement for the control template-primer 
set. Thus, the decrease in efficiency during amplification time can be accounted for by the loss in activity of the enzyme. These later results also 
demonstrate that neither the primers nor the dNTP were limiting during the re.action, and that the kinetic approach followed provides reliable esti- 
mates of average efficiency and of the number of mRNA copies. Data include results from the number of different donors indicated in parentheses. 
amplification reactions (Table 2). The kinetic method used 
to estimate mRNA yielded the expected known number 
of copies  of control synthetic RNA  template. The value 
of amplification efficiency  of control  template  calculated 
directly from the observed DNA amounts and the formula 
N  =  No (1  +  E) n was within experimental error of values 
obtained using the kinetic measurement corrected for Taq 
polymerase decay. 
Freshly isolated monocytes ~pressed both TF and TFPI 
messages, but whereas the levels of TF message reached  a 
maximum after 3 h of culture, levels of TFPI message con- 
tinued to increase for at least 48 h. Thus, the increase in TFPI 
mRNA coincided in time with the specific decreases in TF 
activity measured using functional assays with purified com- 
ponents. 
To further examine the relationship between TFPI and 
TF expression,  TFPI protein was measured in cell extracts 
(1% Triton X-100)  and culture supernatants by EIA using 
monospecific monoclonal and polyclonal IgG as capture and 
detection antibodies respectively. Results from these experi- 
ments show that TFPI antigen was detected in freshly iso- 
lated monocytes at 250 pg/mg of total cell protein and at 
a maximum value of 570 pg/mg by 48 h of culture with 
LPS (Table 2). In the absence of stimulus TFPI antigen levels 
were 2.7-,  2.4- and 2.3-fold above those in freshly isolated 
monocytes at 3, 20, and 48 h. The molar ratio TF/TFPI varied 
during culture and was 0.7,  1.0, 3.4, and 1.7 at 0, 3, 24, 
and 48 h in stimulated cultures and 0.25, 0.45, 0.32, and 
0.28 in unstimulated cultures respectively. The TF activity 
calculated as mole factor Xa generated per mole of TF was 
better correlated with TF/TFPI ratios than with TF protein 
levels. At the concentrations of factors VII and X  used in 
these studies,  TF activity in stimulated cultures was 6  x 
102A, 2  x  103A, 11  x  104A and 2.6  x  103A at 0, 3, 24, 
and 48 h, respectively. In contrast, TF protein levels were 
4.5,  7.5,  35.0, and 25.5 pmole/mg cell protein. 
Discussion 
The studies described here demonstrate the simultaneous 
expression of TF and TF mRNA by human blood mono- 
cytm. Steady-state levels of both TF and TI~I mRNA changed 
during cell culture, but the kinetic profile for each of the 
two mRNA species was ~t.  The highest ratios of TFPI 
to TF mRNA coincided in time with low levels of TF ac- 
tivity measured specifically using purified factors VIIa and X. 
Demonstration of specific mRNA is essential to differen- 
tiate de novo endogenous expression from endocytosis and 
subsequent secretion of ingested protein. It has been reported 
that lipoprotein internalized by monocytes/macrophages  can 
be recycled later to the plasma membrane and released into 
the culture medium (35).  Since plasma TFPI is largely as- 
sociated with lipoproteins, it is possible that a fraction of 
the TFPI demonstrated by immunological  methods represents 
endocytosed protein. Similarly, functional inhibitor measure- 
ments are not a good parameter of TFFI gene expression, 
since net TF activity is always detected. Absolute levels of 
TF and TFPI mRNA were estimated using a quantitative 
1852  Expression of Extrinsic  Coagulation Pathway Inhibitor by Human Monocytes RT-PCR approach based on direct eflficiency determination 
from amplification kinetics. Using this method, low copy 
numbers of both messages were detected on freshly isolated 
nonstimulated monocytes. 
In contrast to TF activity, lipid cofactor activity increased 
slightly, as reflected in the ability of monocytes to provide 
sites for effldent assembly of the intrinsic pathway protease 
components. Thus, the decrease in procoagulant activity was 
specific for the extrinsic pathway components. 
The biological importance of TFPI in the regulation of 
blood coagulation in vivo has not yet been established.  How- 
ever, very suggestive evidence for a role of TFPI in the con- 
trol of hemostasis has been obtained in sublethal disseminated 
intravascular coagulation (DIC) models. Depletion of TFPI 
in rabbits  treated with  anti-TFPI  antibodies rendered the 
animals susceptible to endotoxin administered intravenously 
(36). Low doses of TF induced DIC in TFPI-depleted rabbits 
but had no demonstrable effect on intact animals (37). From 
these studies, it has been proposed that the inhibitor is im- 
portant in maintaining low basal levels of TF activity that 
may be expressed under physiological conditions (9, 36, 37). 
The results presented here are also consistent with this hy- 
pothesis. Neither procoagulant nor inhibitory activity were 
expressed at detectable levels in freshly isolated monocytes. 
However, mRNA and protein were consistently identified. 
It is possible that the low levels of functional TF expressed 
by monocytes are balanced by concomitantly generated TFPL 
The simultaneous generation of TF and TFPI and the for- 
mation of inactive TF/TFPI complexes may serve to limit 
the excessive accumulation of functional TF at inflammatory 
sites, and to check functional TF expression on circulating 
and marginated monocytes. 
Endothelial cells, megakaryocytes, and several continuous 
cell lines including monoblastoid U-932 cells, have been shown 
to express TFPI mRNA. However, RNA isolated from di- 
verse  human  tissues  and  cells,  including  liver  and  bone 
marrow-derived cells, did not hybridize with TFPI probes 
in Northern blots (14).  To our knowledge, there are only 
two additional reports (published as abstracts) on the subject 
of monocyte/macrophage TFPI mRNA expression (38, 39). 
One of the reports indicates that human monocytes in ad- 
herent cultures express TFPI mRNA upon stimulation with 
endotoxin (38).  In contrast, the other report indicates that 
expression of TFPI does not increase upon endotoxin stimu- 
lation in adherent cultures (39). The apparent contradiction 
between these two previous studies both using Northern blot 
analysis of mRNA, may reflect differences in monocyte iso- 
lation and culture protocols and in the sensitivity and efficien- 
des of the hybridization protocols. 
The RT-PCR technique used here demonstrated that freshly 
isolated monocytes express TFPI and that its expression is 
inducible concomitantly with TF during short-term culture 
in vitro in the presence of endotoxin. Regulation of mono- 
cyte TF activity at neoplastic, inflammatory, and atherosderotic 
sites can thus be mediated by TFPI generated locally indepen- 
dently of intravascular sources. 
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